Clinical Trial Update: Current Adoption of Composite Indices in Evaluating Rheumatoid Arthritis Patients: An Observational Study

View source ↗

Summary

Pfizer-sponsored observational trial evaluating the adoption of composite indices for assessing rheumatoid arthritis has completed, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Snippet

Sponsor: Pfizer | Conditions: Rheumatoid Arthritis | Status: COMPLETED | Results posted: 2013-02-04